Brucellosis in humans: Why is it so elusive?

Reviews and Research in Medical Microbiology

Volumn 20, Issue 4, 2009, Pages 63-73

  Vassalos, Constantine M ^a,b   Economou, Vangelis ^b   Vassalou, Evdokia ^a   Papadopoulou, Chryssanthy ^b  

^a National School of Public Helth   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Chronic; Combination therapy; Human brucellosis; Integration; Maintenance in nature; Relapses; Seronegativity

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; RIFAMPICIN; STREPTOMYCIN; VIRULENCE FACTOR;

ACUTE DISEASE; AIR; ANALYTIC METHOD; ANIMAL PRODUCT; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATION; BIOLOGICAL WARFARE AGENT; BRUCELLA ABORTUS; BRUCELLA CANIS; BRUCELLA MELITENSIS; BRUCELLA SUIS; BRUCELLOSIS; CHRONIC DISEASE; CLINICAL FEATURE; DOMESTIC ANIMAL; ENDEMIC DISEASE; ENDOCARDITIS; EUROPE; EXPOSURE; FETOTOXICITY; GRAM NEGATIVE BACTERIUM; HEMATOLOGIC DISEASE; HOST RANGE; HUMAN; INCIDENCE; INFECTION RISK; LABORATORY TEST; MARINE MAMMAL; MIGRATION; NEUROLOGIC DISEASE; NONHUMAN; OCCUPATION; PATHOGENICITY; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RELAPSE; REVIEW; TRAVEL; ZOONOSIS;

EID: 74249089395     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MRM.0b013e3283344b5a     Document Type: Review

References (80)

1. Seimenis A, Morelli D, Mantovani A. Zoonoses in the Mediterranean region. Ann Ist Super Sanita 2006; 42:437-445.
2. Charissis N, Vassalos CM. Brucellosis. In Biological warfare agents. Ekdoseis Korontzis: Athens; 2009 (in press).
3. Moreno E, Stackenbrandt E, Dorsch M, Wolters J, Busch M, Mayer H. Brucella abortus 16S rRNA and lipid A reveal a phylogenetic relationship with members of the alpha-2 subdivision of the class proteobacteria. J Bacteriol 1990; 172: 3569-3576.
4. Osterman B, Moriyón I. International Committee on Systematics of Prokaryotes Subcommittee on the taxonomy of Brucella. Minutes of the meeting, 17 September 2003, Pamplona, Spain. Int J Syst Evol Microbiol 2006; 56:1173-1175. (Pubitemid 43820853)
5. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med 2005; 352:2325-2336.
6. Conner MM, Ebinger MR, Blanchong JA, Cross PC. Infectious disease in cervids in North America. Ann NY Acad Sci 2008; 1134:146-172.
7. Scholz HC, Hubalek Z, Sedláček I, Vergnaud G, Tomaso H, Al Dahoul S, et al. Brucella microti sp. nov., isolated from the common vole Microtus arvalis. Int J Syst Evol Microbiol 2008; 58:375-382.
8. Dawson CE, Stubberfield EJ, Perrett LL, King AC, Whatmore AM, Bashiruddin JB, et al. Phenotypic and molecular characterization of Brucella isolates from marine mammals. BMC Microbiol 2008; 8:224.
9. Schlabritz-Loutsevitch NE, Whatmore AM, Quance CR, Koylass MS, Cummins LB, Dick EJ Jr, et al. A novel Brucella isolate in association with two cases of stillbirth in nonhuman primates - first report. J Med Primatol 2009; 38:70-73.
10. De BK, Stauffer L, Koylass MS, Sharp SE, Gee JE, Helsel LO, et al. Novel Brucella strain (BO1) associated with a prosthetic breast implant infection. J Clin Microbiol 2008; 46:43-49.
11. Tsolis RM, Seshadri R, Santos RL, Sangari FJ, Garcia Lobo JM, de Jong MF, et al. Genome degradation in Brucella ovis corresponds with narrowing of its host range and tissue tropism. PloS ONE 2009; 4:e5519.
12. Burgdorfer W, Varma MGR. Trans-stadial and transovarial development of disease agents in arthropods. Annu Rev Entomol 1967; 12:347-376.
13. Acha P, Szyfrer B. Brucellosis. In Zoonoses and communicable diseases common to man and animals. Bacterioses and mycoses. 3rd ed. Washington, DC: Pan American Health Organization; 2001. pp. 40-67.
14. Corbel MJ (principal author). Brucellosis in humans and animals. Geneva: World Health Organization; 2006.
15. International Society for Infectious Diseases. Program for Monitoring Emerging Diseases. http://www.promedmail.org.
16. Farina F, Fuser R, Rossi M, Scotton PG. Brucellosis outbreak in Treviso province caused by infected cheese from an endemic area. Infez Med 2008; 16:154-157.
17. Official Journal of the European Union. Commission decision of 5 August 2009. 2009; L/204/39-42.
18. Office International des Epizooties. Zoonoses in humans. In World Animal Health Information Database 2006 to 2008. http://www.oie.int/wahis/public.php? page=country-zoonoses.
19. National statistical office of Mongolia. Mongolian statistical yearbook. 2007.
20. MehrNews Agency. http://www.mehnews.com/en/NewsDetail. asp?NewsID=901392 (accessible on 23 June 2009).
21. Al-Tawfiq JA, AbuKhamsin A. A 24-year study of the epidemiology of human brucellosis in a health-care system in Eastern Saudi Arabia. J Infect Public Health 2009; 2:81-85.
22. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis 2006; 6:91-99.
23. Mantur BG, Amarnath SK, Shinde RS. Review of clinical and laboratory features of human brucellosis. Indian J Med Microbiol 2007; 25:188-202.
24. Jennings GJ, Hajjeh RA, Girgis FY, Fadeel MA, Maksoud MA, Wasfy MO, et al. Brucellosis as a cause of acute febrile illness in Egypt. Trans R Soc Trop Med Hyg 2007; 101:707-713.
25. Gargouri N, Walke H, Belbeisi A, Hadadin A, Salah S, Ellis A, et al. Estimated burden of human Salmonella, Shigella, and Brucella in Jordan, 2003-2004. Foodborne Pathog Dis 2009; 6:481-486.
26. National Statistical Service of Greece. Cases of infectious diseases/ discharged patients: 1997 to 2005. http://www.statistics. gr/portal/page/portal/ ESYE/.
27. Vassalos CM, Papadopoulou C, Vakalis N. Blastocystosis: emerging or re-emerging potential zoonosis? Vet Ital 2008; 44:679-684.
28. Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. Lancet Infect Dis 2007; 7:775-786.
29. Guerra H. The Brucellae and their success as pathogens. Crit Rev Microbiol 2007; 33:325-331.
30. Fugier E, Pappas G, Gorvel J-P. Virulence factors in brucellosis: implications for aetiopathogenesis and treatment. Exp Rev Mol Med 2007; 9:1-10.
31. Rajashekara G, Covert J, Petersen E, Eskra L, Splitter G. Genomic island 2 of Brucella melitensis is a major virulence determinant: functional analyses of genomic islands. J Bacteriol 2008; 190:6243-6252.
32. Moreno E, Moriyón I. The genus Brucella. In Prokaryotes (vol. 5). New York: Springer Science + Business Media, LLC; 2006. pp. 315-456.
33. Gorvel J-P. Brucella: a Mr 'Hide' converted into Dr Jekyl. Microbe Infect 2008; 10:1010-1013.
34. Rambow-Larsen AA, Rajashekara G, Petersen E, Splitter G. Putative quorum-sensing regulator BlxR of Brucella melitensis regulates virulence factors including the type IV secretion system and flagella. J Bacteriol 2008; 190:3274-3282.
35. Watarai M, Kim S, Erdenebaatar J, Makino S, Horiuchi M, Shirahatas T, et al. Cellular prion protein promotes Brucella infection into macrophages. J Exp Med 2003; 198:5-17.
36. Bukata L, Altabe S, de Mendoza D, Ugalde RA, Comerci DJ. Phosphatidylethanolamine synthesis is required for optimal virulence of Brucella abortus. J Bacteriol 2008; 190:8197-8203.
37. Oliveira SC, de Oliveira F, Macedo GC, de Almeida LA, Carvalho NB. The role of innate immune receptors in the control of Brucella abortus infection: Toll-like receptors and beyond. Microbe Infect 2008; 10:1005-1009.
38. Reza SJ, Alireza R, Mostafa A, Alireza K, Mehrdad H. Association of tumor necrosis factor-α-308 (G→A) polymorphism and susceptibility to brucellosis. J Microbiol Immunol Infect 2009; 42:22-26.
39. Rasouli M, Kiany S, Behbin M. Interleukin-10 gene polymorphisms and susceptibility to brucellosis in Iranian patients. Iran J Immunol 2008; 5:131-135.
40. Bravo MJ, Colmenero JD, Queipo-Ortuño MI, Alonso A, Caballero A. TGF-beta1 and IL-6 gene polymorphism in Spanish brucellosis patients. Cytokine 2008; 44:18-21.
41. Zwerdling A, Delpino MV, Pasquevich KA, Barrionuevo P, Cassataro J, García Samartino C, et al. Brucella abortus activates human neutrophils. Microbes Infect 2009; 11:689-697.
42. Giambartolomei GH, Delpino MV, Cahanovich ME, Wallach JC, Baldi PC, Velikovsky CA, Fossati CA. Diminished production of T helper 1 cytokines correlates with T cell unresponsiveness to Brucella cytoplasmic proteins in chronic human brucellosis. J Infect Dis 2002; 186:252-259.
43. Vrioni G, Pappas G, Priavali E, Gartzomika C, Levidiotou S. An eternal microbe: Brucella DNA load persists for years after clinical cure. Clin Infect Dis 2008; 46:131-136.
44. Charissis NS, Vassalos KM. An introduction to foodborne diseases and HACCP systems. Athens, Greece: Mediterranean Zoonoses Control Centre/World Health Organization. Available at http://www.mzcp-zoonoses.gr/.
45. Akcali C, Savas L, Baba M, Turunc T, Seckin D. Cutaneous manifestations in brucellosis: a prospective study. Adv Ther 2007; 24:706-711.
46. Demiroǧlu YZ, TurunçT, Alişkan H, Colakoǧlu S, Arslan H. Brucellosis: retrospective evaluation of the clinical, laboratory and epidemiological features of 151 cases. Mikrobiyol Bul 2007; 41:517-527.
47. Hizel K, Guzel O, Dizbay M, Karakus R, Senol E, Arman D, et al. Age and duration of disease as factors affecting clinical findings and sacroiliitis in brucellosis. Infection 2007; 35:434-437.
48. Sari I, Altuntas F, Hacioglu S, Kocyigit I, Sevinc A, Sacar S, et al. A multicenter retrospective study defining the clinical and hematological manifestations of brucellosis and pancytopenia in a large series: hematological malignancies, the unusual cause of pancytopenia in patients with brucellosis. Am J Hematol 2008; 83:334-339.
49. Rolando I, Olarte L, Vilchez G, Lluncor M, Otero L, Paris M, et al. Ocular manifestations associated with brucellosis: a 26- year experience in Peru. Clin Infect Dis 2008; 46:1338-1345.
50. TurunçT, Demiroǧlu YZ, Alişkan H, Colakoǧlu S, Timurkaynak F, Ozdemir N, et al. Brucellosis in cases of end-stage renal disease. Nephrol Dial Transplant 2008; 23:2344-2349.
51. Sabah AA, Aly AM, Tawab AH, Arafa WA. Brucellosis in Egyptian female patients. J Egypt Soc Parasitol 2008; 38:671-678.
52. Ranjbar M, Rezaiee AA, Hashemi SH, Mehdipour S. Neurobrucellosis: report of a rare disease in 20 Iranian patients referred to a tertiary hospital. East Mediterr Health J 2009; 15:143-148.
53. Kutlu G, Ertem GT, Coskun U, Gomceli YB, Tulec N, Inan LE. Brucella: a cause of peripheral neuropathy. Eur Neurol 2009; 61:33-38.
54. Sharma R, Chisnall C, Cooke RP. Evaluation of in-house and commercial immunoassays for the sero-diagnosis of brucellosis in a nonendemic low prevalence population. J Infect 2008; 56:108-113.
55. Kostoula AG, Dalamaga MA, Deska E, Papadopoulou CV. The evaluation of Rose Bengal test in the laboratory diagnosis of human brucellosis. Mediterr J Infect Parasit Dis 1995; X:95-96.
56. Vrioni G, Kouvardas S, Pagarliota A, Charalampaki N, Tarpatzi A, Zerva L. Serologic diagnosis of human brucellosis using Wright, Rose Bengal, BrucellaCapt and Elisa tests in a nonendemic area in Greece. Clin Microbiol Infect 2007; 13 (s1):643-644.
57. Kostoula A, Bobogianni H, Vrioni G, Dea A, Paraschou P, Levidiotou-Stefanou S. Detection of Brucella IgG, IgM and IgA antibodies with ELISA method in patients with brucellosis. Clin Microbiol Infect 2001; 7 (s1):108.
58. Potasman I, Even L, Banai M, Cohen E, Angel D, Jaffe M. Brucellosis: an unusual diagnosis for a seronegative patient with abscesses, osteomyelitis, and ulcerative colitis. Rev Infect Dis 1991; 13:1039-1042.
59. Queipo-Ortuño MI, Tena F, Colmenero JD, Morata P. Comparison of seven commercial DNA extraction kits for the recovery of Brucella DNA from spiked human serum samples using real-time PCR. Eur J Clin Microbiol Infect Dis 2008; 27:109-114.
60. Surucuoglu S, El S, Ural S, Gazi H, Kurutepe S, Taskiran P, et al. Evaluation of real-time PCR method for rapid diagnosis of brucellosis with different clinical manifestations. Pol J Microbiol 2009; 58:15-19.
61. Vrioni G, Gartzonika C, Kostoula A, Boboyianni C, Papadopoulou C, Levidiotou S. Application of a polymerase chain reaction enzyme immunoassay in peripheral whole blood and serum specimens for diagnosis of acute human brucellosis. Eur J Clin Microbiol Infect Dis 2004; 23:194-199.
62. Queipo-Ortuño MI, Colmenero JD, Bravo MJ, García- Ordoñez MA, Morata P. Usefulness of a quantitative real-time PCR assay using serum samples to discriminate between inactive, serologically positive and active human brucellosis. Clin Microbiol Infect 2008; 14:1128-1134.
63. Briones-Lara E, Palacios-Saucedo Gdel C, Martínez-Vázquez IO, Morales-Loredo A, Bilbao-Chávez Ldel P. Response to the treatment of brucellosis among children. Evaluation with Huddleson reaction and PCR. Rev Med Inst Mex Seguro Soc 2007; 45:615-622.
64. Queipo-Ortuño MI, Colmenero JD, Bermudez P, Bravo MJ, Morata P. Rapid differential diagnosis between extrapulmonary tuberculosis and focal complications of brucellosis using a multiplex real-time PCR assay. PLoS ONE 2009; 4:e4526.
65. Scholz HC, Martin Pfeffer M, Angela Witte A, Neubauer H, Al Dahouk S, Wernery U, et al. Specific detection and differentiation of Ochrobactrum anthropi, Ochrobactrum intermedium and Brucella spp. by a multiprimer PCR that targets the recA gene. J Med Microbiol 2008; 57:64-71.
66. Almendra C, Silva TL, Beja-Pereira A, Ferreira AC, Ferrão-Beck L, de Sá MI, et al. 'HOOF-Print' genotyping and haplotype inference discriminates among Brucella spp. isolates from a small spatial scale. Infect Genet Evol 2009; 9:104-107.
67. Hinić V, Brodard I, Thomann A, Cvetnić Z, Makaya PV, Frey J, et al. Novel identification and differentiation of Brucella melitensis, B. abortus, B. suis, B. ovis, B. canis, and B. neotomae suitable for both conventional and real-time PCR systems. J Microbiol Methods 2008; 75:375-378.
68. Kattar MM, Jaafar RF, Araj GF, Le Fleche P, Matar GM, Rached RA, et al. Evaluation of a multilocus variable-number tandemrepeat analysis scheme for typing human Brucella isolates in a region of brucellosis endemicity. J Clin Microbiol 2008; 46:3935-3940.
69. Sayan M, Yumuk Z, Bilenoglu O, Erdenling S, Willke A. Genotyping of Brucella melitensis by rpoB gene analysis and reevaluation of conventional serotyping method. Jpn J Infect Dis 2009; 62:160-163.
70. Ohtsuki R, Kawamoto K, Kato Y, Shah MM, Ezaki T, Makino SI. Rapid detection of Brucella spp. by the loop-mediated isothermal amplification method. J Appl Microbiol 2008; 104:1815-1823.
71. Turkmani A, Ioannidis A, Christidou A, Psaroulaki A, Loukaides F, Tselentis Y. In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Ann Clin Microbiol Antimicrob 2006; 5:24.
72. Aliskan H, Can F, Demirbilek M, Colakoglu S, Yazici C, Arslan H. Evaluation of the E-test and broth dilution methods for susceptibility testing of Brucella melitensis. Clin Microbiol Infect 2008; 14 (s7):S718.
73. Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systemic review and metaanalysis of randomised controlled trials. Br Med J 2008; 336:701-704.
74. Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Medicine 2007; 4:e317.
75. Pappas G, Seitaridis S, Akritidis N, Tsianos E. Treatment of Brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int J Antimicrob Agents 2004; 24:502-507.
76. Al-Tawfiq JA. Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther 2008; 6:109-120.
77. MZCP/WHO. Report on the third workshop on human and animal brucellosis. Epidemiological surveillance in the MZCP countries. 1999; MZCP/Bruc/98.1:1-47.
78. Martins H, Garin-Bastuji B, Lima F, Flor L, Pina Fonseca A, Boinas F. Eradication of bovine brucellosis in the Azores, Portugal: outcome of a 5-year programme (2002-2007) based on test-and-slaughter and RB51 vaccination. Prev Vet Med 2009; 90:80-89.
79. Garin-Bastuji B. Reference laboratory networking: the European experience in brucellosis. Dev Biol (Basel) 2007; 128:131-138.
80. Atkins HS, Spencer S, Brew SD, Laws TR, Thirlwall RE, Macmillan AP, et al. Efficacy of moxifloxacin or gatifloxacin as prophylaxis against murine Brucella melitensis infection. Int J Antimicrob Agents 2009; 34:471-473.